← All trials
NCT05410925
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2023
- Primary completion
- Sep 1, 2025
- Completion date
- Jan 1, 2026
- First posted
- Jun 8, 2022
- Last posted
- Jul 13, 2022
- Enrollment
- 2000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nanjing Medical UniversityLead sponsor
- Nanjing Medical UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.